CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
15 Nov 2024 //
GLOBENEWSWIRE
J&J Bolsters Rybrevant-Lazcluze Case Vs AZ`s Tagrisso With Survival Data
09 Sep 2024 //
FIERCE PHARMA
RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
08 Sep 2024 //
GLOBENEWSWIRE
LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment
30 Aug 2024 //
GLOBENEWSWIRE
FDA Roundup: August 20, 2024
20 Aug 2024 //
PR NEWSWIRE
PALOMA-2: Amivantamab/Lazertinib Shows Response, Safety In EGFR+ NSCLC
03 Jun 2024 //
PR NEWSWIRE
PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC
03 Jun 2024 //
GLOBENEWSWIRE
PALOMA-3: 5-Min Subcut Amivantamab Reduced Infusion Reactions 5-Fold
31 May 2024 //
PR NEWSWIRE
RYBREVANT® Plus Lazertinib Shows Longer PFS Vs Osimertinib In EGFR+ NSCLC
31 May 2024 //
PR NEWSWIRE
J&J Submits sBLA and NDA to U.S. FDA Seeking Approval of RYBREVANT
21 Dec 2023 //
PR NEWSWIRE
J&J details Tagrisso-topping data for Rybrevant, Leclaza combo
24 Oct 2023 //
PR NEWSWIRE
J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win
29 Sep 2023 //
ENDPTS
Treatment with RYBREVANT and Lazertinib Showed Survival in Advanced NSCLC
11 Sep 2023 //
PR NEWSWIRE
Janssen Announces Data Supporting Safety and Efficacy of RYBREVANT + Lazertinib
26 Jul 2022 //
PRNEWSWIRE
New Data on RYBREVANT+Lazertinib Show Early Activity in Patients with NSCLC
19 Sep 2021 //
PRNEWSWIRE
Janssen’s Anti-EGFR Combo Tackles Lung Cancer Ahead Of Phase 3 Tagrisso Showdown
20 Sep 2020 //
FIERCE BIOTECH
Yuhan signs $1.25b licensing deal with Janssen for new lung cancer drug
02 Nov 2018 //
KOREA HERALD